miR‑204‑5p promotes apoptosis and inhibits migration of gastric cancer cells by targeting HER‑2

Yang,Shu; Chen,Binni; Zhang,Baogen; Li,Caiping; Qiu,Yuena; Yang,Hanhui; Huang,Zhongxin

doi:10.3892/mmr.2020.11367

miR‑204‑5p promotes apoptosis and inhibits migration of gastric cancer cells by targeting HER‑2

Authors:
- Shu Yang
- Binni Chen
- Baogen Zhang
- Caiping Li
- Yuena Qiu
- Hanhui Yang
- Zhongxin Huang
View Affiliations

Affiliations: Department of Traditional Chinese Medicine, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian 362000, P.R. China, Department of Ophthalmology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian 362000, P.R. China, Department of Traditional Chinese Medicine, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian 362000, P.R. China, Department of Endoscopy Room, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian 362000, P.R. China, Department of Pathology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian 362000, P.R. China
Published online on: July 28, 2020 https://doi.org/10.3892/mmr.2020.11367
Pages: 2645-2654
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer is one of the most common types of cancer worldwide, with a high incidence and mortality rate. MicroRNAs (miRs) play an important role in tumorigenesis, cell proliferation, migration, apoptosis and metastasis of cancer. The present study aimed to investigate the role and potential mechanism of miR‑204‑5p in gastric cancer. The mRNA expression levels of miR‑204‑5p in gastric cancer were determined by reverse transcription‑quantitative PCR. Cell proliferation was determined using Cell Counting Kit‑8 and colony formation assays. Flow cytometry analysis was performed to detect the cell apoptosis rate. Wound healing and Transwell assays were carried out to determine the cell migration and invasion rates, respectively. A putative binding site of miR‑204‑5p in the 3' untranslated region of human epidermal growth factor receptor 2 (HER‑2) was predicted using a bioinformatics algorithm and confirmed using a dual‑luciferase reporter assay. miR‑204‑5p levels were downregulated in gastric cancer cells. Overexpression of miR‑204‑5p significantly inhibited cell proliferation and decreased cell colony formation. Additionally, miR‑204‑5p decreased the migration and invasion rates of gastric cancer cells. Furthermore, an increased apoptotic rate was detected following overexpression of miR‑204‑5p, along with increased expression levels of Bax and decreased expression levels of Bcl‑2. HER‑2 was a direct target of miR‑204‑5p, and inhibition of HER‑2 acted as a tumor suppressor by inhibiting cell proliferation, migration and invasion, and promoting cell apoptosis, which was reversed by the inhibition of miR‑204‑5p expression. These results suggested that miR‑204‑5p could exert its anti‑tumor function by inhibiting cell proliferation, migration and invasion, and promoting cell apoptosis via regulation of HER‑2, which may be a potential therapeutic target for gastric cancer.

View Figures

View References

1	Zhang B, Yin Y, Hu Y, Zhang J, Bian Z, Song M, Hua D and Huang Z: MicroRNA-204-5p inhibits gastric cancer cell proliferation by downregulating USP47 and RAB22A. Med Oncol. 32:26452015.
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Sheikh IA, Mirza Z, Ali A, Aliev G and Ashraf GM: A proteomics based approach for the identification of gastric cancer related markers. Curr Pharm Des. 22:804–811. 2016. View Article : Google Scholar : PubMed/NCBI
4	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
5	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
6	Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, et al: Global surveillance of cancer survival 1995–2009: Analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 385:977–1010. 2015. View Article : Google Scholar : PubMed/NCBI
7	Hundahl SA: Staging, stage migration, and patterns of spread in gastric cancer. Semin Radiat Oncol. 12:141–149. 2002. View Article : Google Scholar : PubMed/NCBI
8	Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, Lemmens VE and de Hingh IH: Peritoneal carcinomatosis of gastric origin: A population-based study on incidence, survival and risk factors. Int J Cancer. 134:622–628. 2014. View Article : Google Scholar : PubMed/NCBI
9	Tan MC, Balakrishnan M and Graham DY: Gastric cancer worldwide except Japan. Gastric Cancer. Shiotani A: Springer; Singapore: pp. 17–28. 2019, View Article : Google Scholar
10	Song H, Zhu J and Lu D: Molecular-targeted first-line therapy for advanced gastric cancer. Cochrane Database Syst Rev. 7:CD0114612016.PubMed/NCBI
11	Ohno T, Yokoyama Y, Aihara R, Mochiki E, Asao T and Kuwano H: Sudden bilateral sensorineural hearing loss as the presenting symptom of meningeal carcinomatosis of gastric cancer: Report of a case. Surg Today. 40:561–565. 2010. View Article : Google Scholar : PubMed/NCBI
12	Jansen EP, Saunders MP, Boot H, Oppedijk V, Dubbelman R, Porritt B, Cats A, Stroom J, Olmos RV, Bartelink H and Verheij M: Prospective study on late renal toxicity following postoperative chemoradiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys. 67:781–785. 2007. View Article : Google Scholar : PubMed/NCBI
13	Boku N: HER2-positive gastric cancer. Gastric Cancer. 17:1–12. 2014. View Article : Google Scholar : PubMed/NCBI
14	Kepil N, Batur S, Sonmez Wetherilt C and Erdamar Cetin S: Human epidermal growth factor receptor 2 (HER-2) status evaluation in advanced gastric cancer using immunohistochemistry versus silver in situ hybridization. Bosn J Basic Med Sci. 17:109–113. 2017.PubMed/NCBI
15	Mishra S, Yadav T and Rani V: Exploring miRNA based approaches in cancer diagnostics and therapeutics. Crit Rev Oncol Hematol. 98:12–23. 2016. View Article : Google Scholar : PubMed/NCBI
16	Yu J, Feng J, Zhi X, Tang J, Li Z, Xu Y, Yang L, Hu Z and Xu Z: Let-7b inhibits cell proliferation, migration, and invasion through targeting Cthrc1 in gastric cancer. Tumour Biol. 36:3221–3229. 2015. View Article : Google Scholar : PubMed/NCBI
17	Zhu ED, Li N, Li BS, Li W, Zhang WJ, Mao XH, Guo G, Zou QM and Xiao B: miR-30b, down-regulated in gastric cancer, promotes apoptosis and suppresses tumor growth by targeting plasminogen activator inhibitor-1. PLoS One. 9:e1060492014. View Article : Google Scholar : PubMed/NCBI
18	Yin Y, Zhang B, Wang W, Fei B, Quan C, Zhang J, Song M, Bian Z, Wang Q, Ni S, et al: miR-204-5p inhibits proliferation and invasion and enhances chemotherapeutic sensitivity of colorectal cancer cells by downregulating RAB22A. Clin Cancer Res. 20:6187–6199. 2014. View Article : Google Scholar : PubMed/NCBI
19	Liang Y, Zhang CD, Zhang C and Dai DQ: DLX6-AS1/miR-204-5p/OCT1 positive feedback loop promotes tumor progression and epithelial-mesenchymal transition in gastric cancer. Gastric Cancer. 23:212–227. 2020. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
22	Wang QX, Zhu YQ, Zhang H and Xiao J: Altered miRNA expression in gastric cancer: A systematic review and meta-analysis. Cell Physiol Biochem. 35:933–944. 2015. View Article : Google Scholar : PubMed/NCBI
23	Shin VY and Chu KM: MiRNA as potential biomarkers and therapeutic targets for gastric cancer. World J Gastroenterol. 20:10432–10439. 2014. View Article : Google Scholar : PubMed/NCBI
24	Shi Y, Wang Z, Zhu X, Chen L, Ma Y, Wang J, Yang X and Liu Z: Exosomal miR-1246 in serum as a potential biomarker for early diagnosis of gastric cancer. Int J Clin Oncol. 25:89–99. 2020. View Article : Google Scholar : PubMed/NCBI
25	Li Y, Sun H, Guan J, Ji T and Wang X: Serum microRNA-381: A potential marker for early diagnosis of gastric cancer. Yonsei Med J. 60:720–726. 2019. View Article : Google Scholar : PubMed/NCBI
26	Liu L, Wang J, Li X, Ma J, Shi C, Zhu H, Xi Q, Zhang J, Zhao X and Gu M: miR-204-5p suppresses cell proliferation by inhibiting IGFBP5 in papillary thyroid carcinoma. Biochem Biophys Res Commun. 457:621–626. 2015. View Article : Google Scholar : PubMed/NCBI
27	Luan W, Qian Y, Ni X, Bu X, Xia Y, Wang J, Ruan H, Ma S and Xu B: miR-204-5p acts as a tumor suppressor by targeting matrix metalloproteinases-9 and B-cell lymphoma-2 in malignant melanoma. Onco Targets Ther. 10:1237–1246. 2017. View Article : Google Scholar : PubMed/NCBI
28	Chu Y, Jiang M, Du F, Chen D, Ye T, Xu B, Li X, Wang W, Qiu Z, Liu H, et al: miR-204-5p suppresses hepatocellular cancer proliferation by regulating homeoprotein SIX1 expression. FEBS Open Bio. 8:189–200. 2018. View Article : Google Scholar : PubMed/NCBI
29	Jia X, Wen Z, Sun Q, Zhao X, Yang H, Shi X and Xin T: Apatinib suppresses the proliferation and apoptosis of gastric cancer cells via the PI3K/Akt signaling pathway. J BUON. 24:1985–1991. 2019.PubMed/NCBI
30	Shang HS, Lu HF, Lee CH, Chiang HS, Chu YL, Chen A, Lin YF and Chung JG: Quercetin induced cell apoptosis and altered gene expression in AGS human gastric cancer cells. Environ Toxicol. 33:1168–1181. 2018. View Article : Google Scholar : PubMed/NCBI
31	Zhang J, Xing L, Xu H, Wang K, She J, Shi F, Wu H, Sun Y, Gao J and He S: miR-204-5p suppress lymph node metastasis via regulating CXCL12 and CXCR4 in gastric cancer. J Cancer. 11:3199–3206. 2020. View Article : Google Scholar : PubMed/NCBI
32	Wang Y, Zhang H, Ge S, Fan Q, Zhou L, Li H, Bai M, Ning T, Liu R, Wang X, et al: Effects of miR1385p and miR2045p on the migration and proliferation of gastric cancer cells by targeting EGFR. Oncol Rep. 39:2624–2634. 2018.PubMed/NCBI
33	Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J and Ullrich A: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:707–712. 1989. View Article : Google Scholar : PubMed/NCBI
34	Fanotto V, Ongaro E, Rihawi K, Avallone A, Silvestris N, Fornaro L, Vasile E, Antonuzzo L, Leone F, Rosati G, et al: HER-2 inhibition in gastric and colorectal cancers: Tangible achievements, novel acquisitions and future perspectives. Oncotarget. 7:69060–69074. 2016. View Article : Google Scholar : PubMed/NCBI
35	Begnami MD, Fukuda E, Fregnani JH, Nonogaki S, Montagnini AL, da Costa WL Jr and Soares FA: Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol. 29:3030–3036. 2011. View Article : Google Scholar : PubMed/NCBI
36	Di Oto E, Brandes AA, Cucchi MC and Foschini MP: Prognostic impact of HER-2 Subclonal Amplification in breast cancer. Virchows Arch. 471:313–319. 2017. View Article : Google Scholar : PubMed/NCBI
37	Oke OW, Carla L; Gregor and Mariana Chavez-Mac: Outcomes related to delayed initiation of anti-HER 2 therapy in pregnant HER2 positive breast cancer patients. 53rd Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). 2017.
38	Shabbir A, Qureshi MA, Mirza T and Khalid AB: Human epidermal growth factor (Her-2) in gastric and colorectal adenocarcinoma. J Pak Med Assoc. 67:1085–1090. 2017.PubMed/NCBI
39	Sun G, Sun L, Liu Y, Xing H and Wang K: Her-2 expression regulated by downregulation of miR-9 and which affects chemotherapeutic effect in breast cancer. Cancer Gene Ther. 24:194–202. 2017. View Article : Google Scholar : PubMed/NCBI
40	Zhao D, Sui Y and Zheng X: miR-331-3p inhibits proliferation and promotes apoptosis by targeting HER2 through the PI3K/Akt and ERK1/2 pathways in colorectal cancer. Oncol Rep. 35:1075–1082. 2016. View Article : Google Scholar : PubMed/NCBI